Insider trading for Sector - Pharma & Biotech stocks based on disclosures made from Sep 09, 2026 to Sep 23, 2026

Monitor Sector - Pharma & Biotech insider transactions and discover insider buying and selling of stocks from Sep 09, 2026 to Sep 23, 2026.

The latest disclosure under SEC insider trading regulations was reported by CorMedix Inc., where the revocation of 48,909 Phantom Stock of common stock was executed . This transaction was reported to the Securities and Exchange Commission on Sept. 18, 2026.

Insider trading is the trading of a company’s securities by individuals with access to confidential or material non-public information about the company. A company is required to report trading by corporate officers, directors, or other company members with significant access to privileged information to the Securities and Exchange Commission (SEC).

Stock Client Name Client Category Action Reported to Exchange Quantity Post Transaction Holding Traded % Avg. Price Value Security Type
CorMedix Inc
Janet M. Dillione Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 18 Sep 2026 48,909 0 - - Phantom Stock
CorMedix Inc
Janet M. Dillione Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 18 Sep 2026 48,909 117,835 (0%) 0% - Common Stock
Mind Medicine Inc
Andreas Krebs Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 18 Sep 2026 1,629 0 - - Stock Option (Right to Buy)
Mind Medicine Inc
Andreas Krebs Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 35.52 per share. 18 Sep 2026 1,629 21,402 - 35.5 57,862 Common Shares
Mind Medicine Inc
Carol A. Vallone Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 18 Sep 2026 1,086 0 - - Stock Option (Right to Buy)
Mind Medicine Inc
Carol A. Vallone Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 35.52 per share. 18 Sep 2026 1,086 22,296 - 35.5 38,575 Common Shares
Sionna Therapeutics Inc
Michael Cloonan Director, President & CEO Grant, award, or other acquisition of securities at price $ 0.00 per share. 17 Sep 2026 436,100 436,100 - - Non-Qualified Stock Option (right to buy)
Sionna Therapeutics Inc
Michael Cloonan Director, President & CEO Sale or transfer of securities back to the company at price $ 0.00 per share. 17 Sep 2026 436,100 0 - - Non-Qualified Stock Option (right to buy)
Caris Life Sciences Inc (Class A)
Brian J. Brille Director, See Remarks Sale of securities on an exchange or to another person at price $ 30.33 per share. 17 Sep 2026 400,000 230,303 - 30.3 12,132,080 Common Stock
Caris Life Sciences Inc (Class A)
Brian J. Brille Director, See Remarks Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.44 per share. 17 Sep 2026 400,000 630,303 - 2.4 976,000 Common Stock
Caris Life Sciences Inc (Class A)
Brian J. Brille Director, See Remarks Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 17 Sep 2026 400,000 1,600,000 - - Stock Option
Twist Bioscience Corp
Emily M. Leproust Director, Chief Executive Officer Sale of securities on an exchange or to another person at price $ 158.09 per share. 17 Sep 2026 232,173 673,569 (1%) 0% 158.1 36,703,672 Common Stock
Sionna Therapeutics Inc
Elena H. Ridloff CFO and CBO Sale or transfer of securities back to the company at price $ 0.00 per share. 17 Sep 2026 165,440 0 - - Non-Qualified Stock Option (right to buy)
Sionna Therapeutics Inc
Elena H. Ridloff CFO and CBO Grant, award, or other acquisition of securities at price $ 0.00 per share. 17 Sep 2026 165,440 165,440 - - Non-Qualified Stock Option (right to buy)
Sionna Therapeutics Inc
Charlotte McKee CMO and Head of R&D Sale or transfer of securities back to the company at price $ 0.00 per share. 17 Sep 2026 155,700 0 - - Non-Qualified Stock Option (right to buy)
Sionna Therapeutics Inc
Charlotte McKee CMO and Head of R&D Grant, award, or other acquisition of securities at price $ 0.00 per share. 17 Sep 2026 155,700 155,700 - - Non-Qualified Stock Option (right to buy)
Twist Bioscience Corp
Emily M. Leproust Director, Chief Executive Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 26.66 per share. 17 Sep 2026 133,269 901,696 (2%) 0% 26.7 3,552,952 Common Stock
Twist Bioscience Corp
Emily M. Leproust Director, Chief Executive Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 17 Sep 2026 133,269 0 - - Employee Stock Option (right to buy)
Sionna Therapeutics Inc
Michael Cloonan Director, President & CEO Grant, award, or other acquisition of securities at price $ 0.00 per share. 17 Sep 2026 109,025 656,368 - 0 Common Stock
Sionna Therapeutics Inc
Michael Cloonan Director, President & CEO Grant, award, or other acquisition of securities at price $ 0.00 per share. 17 Sep 2026 109,025 765,393 - 0 Common Stock
Sionna Therapeutics Inc
Jennifer Fitzpatrick CLO and Head of Program Mgmt. Grant, award, or other acquisition of securities at price $ 0.00 per share. 17 Sep 2026 103,140 103,140 - - Non-Qualified Stock Option (right to buy)
Sionna Therapeutics Inc
Jennifer Fitzpatrick CLO and Head of Program Mgmt. Sale or transfer of securities back to the company at price $ 0.00 per share. 17 Sep 2026 103,140 0 - - Non-Qualified Stock Option (right to buy)
Soligenix Inc
Robert J. Rubin Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 17 Sep 2026 78,947 78,947 - - Stock Option (Right to Buy)
Soligenix Inc
Gregg Anthony Lapointe Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 17 Sep 2026 78,947 78,947 - - Stock Option (Right to Buy)
Soligenix Inc
Jerome Bernard Zeldis Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 17 Sep 2026 78,947 78,947 - - Stock Option (Right to Buy)
Soligenix Inc
Diane L. Parks Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 17 Sep 2026 78,947 78,947 - - Stock Option (Right to Buy)
Twist Bioscience Corp
Emily M. Leproust Director, Chief Executive Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 17 Sep 2026 75,439 0 - - Employee Stock Option (right to buy)
Twist Bioscience Corp
Emily M. Leproust Director, Chief Executive Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.82 per share. 17 Sep 2026 75,439 977,135 (2%) 0% 8.8 665,372 Common Stock
Kiora Pharma Inc
Keith J. Lane EVP, Clinical and Regulatory Grant, award, or other acquisition of securities at price $ 0.00 per share. 17 Sep 2026 55,000 55,000 - - Stock Option (right to buy)
Sionna Therapeutics Inc
Charlotte McKee CMO and Head of R&D Grant, award, or other acquisition of securities at price $ 0.00 per share. 17 Sep 2026 50,000 78,415 - 0 Common Stock
Sionna Therapeutics Inc
Charlotte McKee CMO and Head of R&D Grant, award, or other acquisition of securities at price $ 0.00 per share. 17 Sep 2026 50,000 128,415 - 0 Common Stock
Sionna Therapeutics Inc
Elena H. Ridloff CFO and CBO Grant, award, or other acquisition of securities at price $ 0.00 per share. 17 Sep 2026 47,269 85,801 - 0 Common Stock
Sionna Therapeutics Inc
Elena H. Ridloff CFO and CBO Grant, award, or other acquisition of securities at price $ 0.00 per share. 17 Sep 2026 47,268 133,069 - 0 Common Stock
Twist Bioscience Corp
Emily M. Leproust Director, Chief Executive Officer Sale of securities on an exchange or to another person at price $ 157.49 per share. 17 Sep 2026 32,260 905,742 (2%) 0% 157.5 5,080,498 Common Stock
Sionna Therapeutics Inc
Jennifer Fitzpatrick CLO and Head of Program Mgmt. Grant, award, or other acquisition of securities at price $ 0.00 per share. 17 Sep 2026 28,133 28,133 - 0 Common Stock
Sionna Therapeutics Inc
Jennifer Fitzpatrick CLO and Head of Program Mgmt. Grant, award, or other acquisition of securities at price $ 0.00 per share. 17 Sep 2026 28,132 56,265 - 0 Common Stock
Twist Bioscience Corp
Emily M. Leproust Director, Chief Executive Officer Sale of securities on an exchange or to another person at price $ 159.53 per share. 17 Sep 2026 23,884 649,685 (1%) 0% 159.5 3,810,250 Common Stock
Dianthus Therapeutics Inc
Edward G. Carr CHIEF ACCOUNTING OFFICER Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.88 per share. 17 Sep 2026 20,000 20,000 - 17.9 357,600 Common Stock
Dianthus Therapeutics Inc
Edward G. Carr CHIEF ACCOUNTING OFFICER Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 17 Sep 2026 20,000 43,818 - - Stock Option (Right to Buy)
Corcept Therapeutics Inc
G. Charles Robb Chief Business Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 17 Sep 2026 17,493 182,507 - - Stock option (right to buy)
Corcept Therapeutics Inc
G. Charles Robb Chief Business Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.27 per share. 17 Sep 2026 17,493 31,156 (0%) 0% 8.3 144,667 Common Stock
Twist Bioscience Corp
Emily M. Leproust Director, Chief Executive Officer Sale of securities on an exchange or to another person at price $ 160.44 per share. 17 Sep 2026 14,493 635,192 (1%) 0% 160.4 2,325,245 Common Stock
Twist Bioscience Corp
Emily M. Leproust Director, Chief Executive Officer Sale of securities on an exchange or to another person at price $ 155.46 per share. 17 Sep 2026 13,378 947,099 (2%) 0% 155.5 2,079,701 Common Stock
Grace Therapeutics Inc
Edward Neugeboren Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 17 Sep 2026 12,200 12,200 - - Stock Option (Right to Buy)
Grace Therapeutics Inc
Vimal Kavuru Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 17 Sep 2026 12,200 12,200 - - Stock Option (Right to Buy)
Grace Therapeutics Inc
S. George Kottayil Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 17 Sep 2026 12,200 12,200 - - Stock Option (Right to Buy)
Twist Bioscience Corp
Emily M. Leproust Director, Chief Executive Officer Sale of securities on an exchange or to another person at price $ 161.49 per share. 17 Sep 2026 11,169 624,023 (1%) 0% 161.5 1,803,715 Common Stock
United Therapeutics Corp
Martine A. Rothblatt Director, Chairperson & CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 117.76 per share. 17 Sep 2026 9,500 333,943 (0%) 0% 117.8 1,118,720 Common Stock
United Therapeutics Corp
Martine A. Rothblatt Director, Chairperson & CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 17 Sep 2026 9,500 413,910 - - Stock Option
Twist Bioscience Corp
Emily M. Leproust Director, Chief Executive Officer Sale of securities on an exchange or to another person at price $ 156.47 per share. 17 Sep 2026 9,097 938,002 (2%) 0% 156.5 1,423,384 Common Stock
United Therapeutics Corp
Paul A. Mahon EVP & GENERAL COUNSEL Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 17 Sep 2026 8,300 47,540 - - Stock Option
United Therapeutics Corp
Paul A. Mahon EVP & GENERAL COUNSEL Exercise or conversion of derivative security received from the company (such as an option) at price $ 146.03 per share. 17 Sep 2026 8,300 53,472 (0%) 0% 146.0 1,212,049 Common Stock
Dianthus Therapeutics Inc
Edward G. Carr CHIEF ACCOUNTING OFFICER Sale of securities on an exchange or to another person at price $ 100.43 per share. 17 Sep 2026 7,928 12,072 - 100.4 796,209 Common Stock
Dianthus Therapeutics Inc
Edward G. Carr CHIEF ACCOUNTING OFFICER Sale of securities on an exchange or to another person at price $ 101.37 per share. 17 Sep 2026 6,771 5,301 - 101.4 686,376 Common Stock
Twist Bioscience Corp
Emily M. Leproust Director, Chief Executive Officer Sale of securities on an exchange or to another person at price $ 152.21 per share. 17 Sep 2026 6,644 968,051 (2%) 0% 152.2 1,011,291 Common Stock
Twist Bioscience Corp
Emily M. Leproust Director, Chief Executive Officer Sale of securities on an exchange or to another person at price $ 154.17 per share. 17 Sep 2026 4,175 960,477 (2%) 0% 154.2 643,661 Common Stock
Dianthus Therapeutics Inc
Edward G. Carr CHIEF ACCOUNTING OFFICER Sale of securities on an exchange or to another person at price $ 102.39 per share. 17 Sep 2026 3,501 1,800 - 102.4 358,467 Common Stock
Twist Bioscience Corp
Emily M. Leproust Director, Chief Executive Officer Sale of securities on an exchange or to another person at price $ 153.40 per share. 17 Sep 2026 3,399 964,652 (2%) 0% 153.4 521,417 Common Stock
United Therapeutics Corp
Paul A. Mahon EVP & GENERAL COUNSEL Sale of securities on an exchange or to another person at price $ 496.58 per share. 17 Sep 2026 2,873 49,020 (0%) 0% 496.6 1,426,662 Common Stock
Twist Bioscience Corp
Emily M. Leproust Director, Chief Executive Officer Sale of securities on an exchange or to another person at price $ 162.31 per share. 17 Sep 2026 2,565 621,458 (1%) 0% 162.3 416,334 Common Stock
Twist Bioscience Corp
Emily M. Leproust Director, Chief Executive Officer Sale of securities on an exchange or to another person at price $ 151.46 per share. 17 Sep 2026 2,440 974,695 (2%) 0% 151.5 369,566 Common Stock
United Therapeutics Corp
Martine A. Rothblatt Director, Chairperson & CEO Sale of securities on an exchange or to another person at price $ 496.21 per share. 17 Sep 2026 2,182 327,507 (0%) 0% 496.2 1,082,721 Common Stock
United Therapeutics Corp
Martine A. Rothblatt Director, Chairperson & CEO Sale of securities on an exchange or to another person at price $ 497.17 per share. 17 Sep 2026 1,953 325,554 (0%) 0% 497.2 970,978 Common Stock
United Therapeutics Corp
Martine A. Rothblatt Director, Chairperson & CEO Sale of securities on an exchange or to another person at price $ 495.11 per share. 17 Sep 2026 1,905 329,689 (0%) 0% 495.1 943,183 Common Stock
United Therapeutics Corp
Martine A. Rothblatt Director, Chairperson & CEO Sale of securities on an exchange or to another person at price $ 494.34 per share. 17 Sep 2026 1,750 331,594 (0%) 0% 494.3 865,096 Common Stock
United Therapeutics Corp
Paul A. Mahon EVP & GENERAL COUNSEL Sale of securities on an exchange or to another person at price $ 495.97 per share. 17 Sep 2026 1,579 51,893 (0%) 0% 496.0 783,132 Common Stock
United Therapeutics Corp
Paul A. Mahon EVP & GENERAL COUNSEL Sale of securities on an exchange or to another person at price $ 497.54 per share. 17 Sep 2026 1,400 47,620 (0%) 0% 497.5 696,561 Common Stock
United Therapeutics Corp
Paul A. Mahon EVP & GENERAL COUNSEL Sale of securities on an exchange or to another person at price $ 499.75 per share. 17 Sep 2026 1,160 45,617 (0%) 0% 499.8 579,712 Common Stock
Dianthus Therapeutics Inc
Edward G. Carr CHIEF ACCOUNTING OFFICER Sale of securities on an exchange or to another person at price $ 103.20 per share. 17 Sep 2026 1,100 700 - 103.2 113,520 Common Stock
Twist Bioscience Corp
Emily M. Leproust Director, Chief Executive Officer Sale of securities on an exchange or to another person at price $ 163.39 per share. 17 Sep 2026 869 620,589 (1%) 0% 163.4 141,988 Common Stock
United Therapeutics Corp
Paul A. Mahon EVP & GENERAL COUNSEL Sale of securities on an exchange or to another person at price $ 498.74 per share. 17 Sep 2026 843 46,777 (0%) 0% 498.7 420,435 Common Stock
Dianthus Therapeutics Inc
Edward G. Carr CHIEF ACCOUNTING OFFICER Sale of securities on an exchange or to another person at price $ 104.39 per share. 17 Sep 2026 700 0 - 104.4 73,073 Common Stock
United Therapeutics Corp
Martine A. Rothblatt Director, Chairperson & CEO Sale of securities on an exchange or to another person at price $ 493.22 per share. 17 Sep 2026 599 333,344 (0%) 0% 493.2 295,436 Common Stock
SAB Biotherapeutics Inc
Alexandra Kropotova CHIEF MEDICAL OFFICER Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. 17 Sep 2026 473 41,853 - - Common Stock
United Therapeutics Corp
Martine A. Rothblatt Director, Chairperson & CEO Sale of securities on an exchange or to another person at price $ 500.09 per share. 17 Sep 2026 468 324,603 (0%) 0% 500.1 234,043 Common Stock
Zoetis (Class A)
Mark Stetter Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 17 Sep 2026 342 880 - - Phantom Stock Unit
United Therapeutics Corp
Martine A. Rothblatt Director, Chairperson & CEO Sale of securities on an exchange or to another person at price $ 499.10 per share. 17 Sep 2026 332 325,071 (0%) 0% 499.1 165,701 Common Stock
United Therapeutics Corp
Paul A. Mahon EVP & GENERAL COUNSEL Sale of securities on an exchange or to another person at price $ 501.58 per share. 17 Sep 2026 320 45,172 (0%) 0% 501.6 160,506 Common Stock
Haleon PLC (ADR)
Alan James Stewart Senior Independent Director Sale or transfer of securities back to the company at price $ 3.38 per share. 17 Sep 2026 242 35,253 (0%) 0% 3.4 818 Ords
United Therapeutics Corp
Martine A. Rothblatt Director, Chairperson & CEO Sale of securities on an exchange or to another person at price $ 501.60 per share. 17 Sep 2026 160 324,443 (0%) 0% 501.6 80,256 Common Stock
United Therapeutics Corp
Martine A. Rothblatt Director, Chairperson & CEO Sale of securities on an exchange or to another person at price $ 497.79 per share. 17 Sep 2026 151 325,403 (0%) 0% 497.8 75,166 Common Stock
United Therapeutics Corp
Paul A. Mahon EVP & GENERAL COUNSEL Sale of securities on an exchange or to another person at price $ 500.80 per share. 17 Sep 2026 125 45,492 (0%) 0% 500.8 62,600 Common Stock
Clene Inc
David J. Matlin Director Grant, award, or other acquisition of securities at price $ 3.28 per share. 16 Sep 2026 434,451 912,275 - 3.3 1,424,999 common stock
Clene Inc
Alison H. Mosca Director, Ten Percent Owner Grant, award, or other acquisition of securities at price $ 3.28 per share. 16 Sep 2026 198,171 478,671 - 3.3 650,001 common stock
Adaptive biotech Corp
Francis Lo Chief People Officer Sale of securities on an exchange or to another person at price $ 28.02 per share. 16 Sep 2026 107,537 228,736 (0%) 0% 28.0 3,013,187 Common Stock
Adaptive biotech Corp
Francis Lo Chief People Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 16 Sep 2026 53,091 79,155 - - Stock Option (right to buy)
Adaptive biotech Corp
Francis Lo Chief People Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.14 per share. 16 Sep 2026 53,091 283,804 (0%) 0% 12.1 644,525 Common Stock
Tenax Therapeutics Inc
Declan Doogan Director Purchase of securities on an exchange or from another person at price $ 1.92 per share. 16 Sep 2026 53,000 55,274 (0%) 0% 1.9 101,760 Common Stock
Harmony Biosciences Holdings Inc
Kumar Budur CHIEF MEDICAL OFFICER Sale of securities on an exchange or to another person at price $ 43.05 per share. 16 Sep 2026 35,852 13,115 - 43.1 1,543,590 Common Stock
Skye Bioscience Inc
Andrew J. Schwab Director, Ten Percent Owner Sale of securities on an exchange or to another person at price $ 1.91 per share. 16 Sep 2026 32,607 142,463 (0%) 0% 1.9 62,279 Common Stock
Harmony Biosciences Holdings Inc
Kumar Budur CHIEF MEDICAL OFFICER Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 16 Sep 2026 25,446 37,500 - - Stock Option
Harmony Biosciences Holdings Inc
Kumar Budur CHIEF MEDICAL OFFICER Exercise or conversion of derivative security received from the company (such as an option) at price $ 30.27 per share. 16 Sep 2026 25,446 48,967 - 30.3 770,250 Common Stock
Immunic Inc
Robert Thorvald Nagel Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 16 Sep 2026 25,370 25,370 - - Stock Option
Altimmune Inc
Linda M. Richardson Chief Commercial Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 16 Sep 2026 24,000 24,000 (0%) 0% 0 Common Stock, par value $0.0001
Altimmune Inc
Linda M. Richardson Chief Commercial Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 16 Sep 2026 24,000 72,000 - - Restricted Stock Units
Adaptive biotech Corp
Francis Lo Chief People Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.12 per share. 16 Sep 2026 23,442 336,273 (0%) 0% 8.1 190,349 Common Stock
Adaptive biotech Corp
Francis Lo Chief People Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 16 Sep 2026 23,442 103,142 - - Stock Option (right to buy)
MapLight Therapeutics Inc
Kristopher L. Hanson General Counsel Sale of securities on an exchange or to another person at price $ 11.67 per share. 16 Sep 2026 16,509 137,044 - 11.7 192,660 Voting Common Stock
Adaptive biotech Corp
Francis Lo Chief People Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.99 per share. 16 Sep 2026 15,629 312,831 (0%) 0% 4.0 62,360 Common Stock
Adaptive biotech Corp
Francis Lo Chief People Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 16 Sep 2026 15,629 65,636 - - Stock Option (right to buy)
Clene Inc
Robert Etherington Director, President & CEO Grant, award, or other acquisition of securities at price $ 3.28 per share. 16 Sep 2026 15,244 55,393 - 3.3 50,000 common stock
Revolution Medicines Inc
Mark A. Goldsmith Director, See Remarks Sale of securities on an exchange or to another person at price $ 199.30 per share. 16 Sep 2026 13,775 253,342 (0%) 0% 199.3 2,745,402 Common Stock
Adaptive biotech Corp
Francis Lo Chief People Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 16 Sep 2026 13,398 24,113 - - Stock Option (right to buy)
Adaptive biotech Corp
Francis Lo Chief People Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.46 per share. 16 Sep 2026 13,398 297,202 (0%) 0% 8.5 113,347 Common Stock
Avalo Therapeutics Inc
Christopher Ryan Sullivan Chief Financial Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 16 Sep 2026 12,394 83,848 - - Stock Option (Right to Buy)
Avalo Therapeutics Inc
Christopher Ryan Sullivan Chief Financial Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.88 per share. 16 Sep 2026 12,394 52,294 - 9.9 122,453 Common Stock
Avalo Therapeutics Inc
Christopher Ryan Sullivan Chief Financial Officer Sale of securities on an exchange or to another person at price $ 16.33 per share. 16 Sep 2026 12,394 39,900 - 16.3 202,437 Common Stock
Roivant Sciences Ltd
James C. Momtazee Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 16 Sep 2026 10,531 10,531 - - Stock Option (Right to Buy)
Roivant Sciences Ltd
Meghan M. Fitzgerald Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 16 Sep 2026 10,531 10,531 - - Stock Option (Right to Buy)
Roivant Sciences Ltd
Keith Manchester Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 16 Sep 2026 10,531 10,531 - - Stock Option (Right to Buy)
Roivant Sciences Ltd
Ilan Oren Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 16 Sep 2026 10,531 10,531 - - Stock Option (Right to Buy)
Roivant Sciences Ltd
Melissa B. Epperly Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 16 Sep 2026 10,531 10,531 - - Stock Option (Right to Buy)
Roivant Sciences Ltd
Daniel Gold Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 16 Sep 2026 10,531 10,531 - - Stock Option (Right to Buy)
Harmony Biosciences Holdings Inc
Kumar Budur CHIEF MEDICAL OFFICER Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 16 Sep 2026 10,406 18,594 - - Stock Option
Harmony Biosciences Holdings Inc
Kumar Budur CHIEF MEDICAL OFFICER Exercise or conversion of derivative security received from the company (such as an option) at price $ 30.69 per share. 16 Sep 2026 10,406 23,521 - 30.7 319,360 Common Stock
Amphastar Pharma Inc
Rong Zhou SENIOR EVP, PRODUCTION CENTER Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.35 per share. 16 Sep 2026 10,000 179,203 (0%) 0% 13.4 133,500 Common Stock
Amphastar Pharma Inc
Rong Zhou SENIOR EVP, PRODUCTION CENTER Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 16 Sep 2026 10,000 19,424 - - Employee Stock Option (right to buy)
Amphastar Pharma Inc
Rong Zhou SENIOR EVP, PRODUCTION CENTER Sale of securities on an exchange or to another person at price $ 23.94 per share. 16 Sep 2026 10,000 169,203 (0%) 0% 23.9 239,404 Common Stock
PTC Therapeutics Inc
Michael Schmertzler Director Sale of securities on an exchange or to another person at price $ 67.83 per share. 16 Sep 2026 9,624 1,296,970 (2%) 0% 67.8 652,796 Common Stock
United Therapeutics Corp
Martine A. Rothblatt Director, Chairperson & CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 117.76 per share. 16 Sep 2026 9,500 333,943 (0%) 0% 117.8 1,118,720 Common Stock
United Therapeutics Corp
Martine A. Rothblatt Director, Chairperson & CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 16 Sep 2026 9,500 423,410 - - Stock Option
Halozyme Therapeutics Inc
Matthew L. Posard Director Sale of securities on an exchange or to another person at price $ 108.04 per share. 16 Sep 2026 8,896 62,839 (0%) 0% 108.0 961,124 Common Stock
Adaptive biotech Corp
Francis Lo Chief People Officer Sale of securities on an exchange or to another person at price $ 28.57 per share. 16 Sep 2026 7,869 220,867 (0%) 0% 28.6 224,817 Common Stock
PTC Therapeutics Inc
Michael Schmertzler Director Sale of securities on an exchange or to another person at price $ 67.35 per share. 16 Sep 2026 7,006 1,306,594 (2%) 0% 67.3 471,854 Common Stock
Altimmune Inc
Linda M. Richardson Chief Commercial Officer Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.24 per share. 16 Sep 2026 6,826 17,174 (0%) 0% 3.2 22,116 Common Stock, par value $0.0001
Revolution Medicines Inc
Stephen M. Kelsey See Remarks Sale of securities on an exchange or to another person at price $ 199.30 per share. 16 Sep 2026 5,484 286,307 (0%) 0% 199.3 1,092,979 Common Stock
Roivant Sciences Ltd
James C. Momtazee Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 16 Sep 2026 5,054 111,959 - 0 Common Shares
Roivant Sciences Ltd
Meghan M. Fitzgerald Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 16 Sep 2026 5,054 41,162 - 0 Common Shares
Roivant Sciences Ltd
Keith Manchester Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 16 Sep 2026 5,054 1,753,457 - 0 Common Shares
Roivant Sciences Ltd
Ilan Oren Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 16 Sep 2026 5,054 123,680 - 0 Common Shares
Roivant Sciences Ltd
Melissa B. Epperly Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 16 Sep 2026 5,054 14,954 - 0 Common Shares
Roivant Sciences Ltd
Daniel Gold Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 16 Sep 2026 5,054 8,965,815 - 0 Common Shares
Inhibrx Biosciences Inc
Jon Faiz Kayyem Director Purchase of securities on an exchange or from another person at price $ 100.00 per share. 16 Sep 2026 5,000 429,360 - 100 500,000 Common Stock
Revolution Medicines Inc
Margaret A. Horn Chief Operating Officer Sale of securities on an exchange or to another person at price $ 199.30 per share. 16 Sep 2026 4,891 149,680 (0%) 0% 199.3 974,792 Common Stock
Halozyme Therapeutics Inc
Matthew L. Posard Director Sale of securities on an exchange or to another person at price $ 108.99 per share. 16 Sep 2026 4,000 58,839 (0%) 0% 109.0 435,964 Common Stock
Revolution Medicines Inc
Jack Anders Chief Financial Officer Sale of securities on an exchange or to another person at price $ 199.30 per share. 16 Sep 2026 3,992 119,216 (0%) 0% 199.3 795,618 Common Stock
Arcutis Biotherapeutics Inc
Masaru Matsuda See Remarks Sale of securities on an exchange or to another person at price $ 25.00 per share. 16 Sep 2026 3,674 112,508 (0%) 0% 25.0 91,853 Common Stock
Rallybio Corp
Wendy K. Chung Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.38 per share. 16 Sep 2026 3,562 3,562 - 2.4 8,478 Common Stock
Rallybio Corp
Wendy K. Chung Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 16 Sep 2026 3,562 0 - - Option (Right to Buy)
Revolution Medicines Inc
Jeffrey Cislini SVP & General Counsel Sale of securities on an exchange or to another person at price $ 199.30 per share. 16 Sep 2026 3,314 52,541 (0%) 0% 199.3 660,491 Common Stock
Halozyme Therapeutics Inc
Matthew L. Posard Director Sale of securities on an exchange or to another person at price $ 106.13 per share. 16 Sep 2026 3,100 74,735 (0%) 0% 106.1 329,009 Common Stock
Halozyme Therapeutics Inc
Matthew L. Posard Director Sale of securities on an exchange or to another person at price $ 106.83 per share. 16 Sep 2026 3,000 71,735 (0%) 0% 106.8 320,484 Common Stock
PTC Therapeutics Inc
Michael Schmertzler Director Sale of securities on an exchange or to another person at price $ 66.58 per share. 16 Sep 2026 2,994 1,313,600 (2%) 0% 66.6 199,341 Common Stock
United Therapeutics Corp
Martine A. Rothblatt Director, Chairperson & CEO Sale of securities on an exchange or to another person at price $ 502.44 per share. 16 Sep 2026 2,160 327,283 (0%) 0% 502.4 1,085,272 Common Stock
Palvella Therapeutics Inc
Kathleen Goin Chief Operating Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.14 per share. 16 Sep 2026 2,154 2,154 - 7.1 15,380 Common Stock
Palvella Therapeutics Inc
Kathleen Goin Chief Operating Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 16 Sep 2026 2,154 2,165 - - Stock Option (Right to Buy)
Palvella Therapeutics Inc
Kathleen Goin Chief Operating Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.08 per share. 16 Sep 2026 2,148 4,302 - 9.1 19,504 Common Stock
Palvella Therapeutics Inc
Kathleen Goin Chief Operating Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 16 Sep 2026 2,148 2,148 - - Stock Option (Right to Buy)
Upstream Bio Inc
Everett Rand Sutherland Director, Chief Executive Officer Sale of securities on an exchange or to another person at price $ 5.49 per share. 16 Sep 2026 2,095 68,717 - 5.5 11,502 Common Stock
United Therapeutics Corp
Martine A. Rothblatt Director, Chairperson & CEO Sale of securities on an exchange or to another person at price $ 498.45 per share. 16 Sep 2026 2,080 331,863 (0%) 0% 498.5 1,036,777 Common Stock
Harmony Biosciences Holdings Inc
Kumar Budur CHIEF MEDICAL OFFICER Sale of securities on an exchange or to another person at price $ 43.01 per share. 16 Sep 2026 1,800 13,115 - 43.0 77,426 Common Stock
Revolution Medicines Inc
Anthony Mancini See Remarks Sale of securities on an exchange or to another person at price $ 199.30 per share. 16 Sep 2026 1,747 42,116 (0%) 0% 199.3 348,183 Common Stock
Palvella Therapeutics Inc
Kathleen Goin Chief Operating Officer Sale of securities on an exchange or to another person at price $ 151.16 per share. 16 Sep 2026 1,659 2,643 - 151.2 250,773 Common Stock
Palvella Therapeutics Inc
Kathleen Goin Chief Operating Officer Sale of securities on an exchange or to another person at price $ 153.24 per share. 16 Sep 2026 1,654 0 - 153.2 253,465 Common Stock
United Therapeutics Corp
Martine A. Rothblatt Director, Chairperson & CEO Sale of securities on an exchange or to another person at price $ 503.53 per share. 16 Sep 2026 1,538 325,745 (0%) 0% 503.5 774,429 Common Stock
Skye Bioscience Inc
Andrew J. Schwab Director, Ten Percent Owner Sale of securities on an exchange or to another person at price $ 1.91 per share. 16 Sep 2026 1,285 5,616 (0%) 0% 1.9 2,454 Common Stock
United Therapeutics Corp
Martine A. Rothblatt Director, Chairperson & CEO Sale of securities on an exchange or to another person at price $ 499.15 per share. 16 Sep 2026 1,220 330,643 (0%) 0% 499.2 608,966 Common Stock
United Therapeutics Corp
Martine A. Rothblatt Director, Chairperson & CEO Sale of securities on an exchange or to another person at price $ 504.17 per share. 16 Sep 2026 1,182 324,563 (0%) 0% 504.2 595,932 Common Stock
Palvella Therapeutics Inc
Kathleen Goin Chief Operating Officer Sale of securities on an exchange or to another person at price $ 152.36 per share. 16 Sep 2026 989 1,654 - 152.4 150,686 Common Stock
Natera Inc
Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS Gift of securities by or to the insider at price $ 0.00 per share. 16 Sep 2026 945 109,914 (0%) 0% 0 Common Stock
Harmony Biosciences Holdings Inc
Kumar Budur CHIEF MEDICAL OFFICER Exercise or conversion of derivative security received from the company (such as an option) at price $ 30.69 per share. 16 Sep 2026 900 14,015 - 30.7 27,621 Common Stock
Harmony Biosciences Holdings Inc
Kumar Budur CHIEF MEDICAL OFFICER Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 16 Sep 2026 900 63,346 - - Stock Option
Harmony Biosciences Holdings Inc
Kumar Budur CHIEF MEDICAL OFFICER Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 16 Sep 2026 900 29,400 - - Stock Option
Harmony Biosciences Holdings Inc
Kumar Budur CHIEF MEDICAL OFFICER Exercise or conversion of derivative security received from the company (such as an option) at price $ 30.27 per share. 16 Sep 2026 900 14,915 - 30.3 27,243 Common Stock
Upstream Bio Inc
Aaron Deykin Chief Medical Officer Sale of securities on an exchange or to another person at price $ 5.49 per share. 16 Sep 2026 895 32,302 - 5.5 4,914 Common Stock
Upstream Bio Inc
Michael Paul Gray CFO and COO Sale of securities on an exchange or to another person at price $ 5.49 per share. 16 Sep 2026 853 27,942 - 5.5 4,683 Common Stock
Harmony Biosciences Holdings Inc
Kumar Budur CHIEF MEDICAL OFFICER Sale of securities on an exchange or to another person at price $ 43.00 per share. 16 Sep 2026 800 13,115 - 43 34,400 Common Stock
United Therapeutics Corp
Martine A. Rothblatt Director, Chairperson & CEO Sale of securities on an exchange or to another person at price $ 501.52 per share. 16 Sep 2026 708 329,443 (0%) 0% 501.5 355,077 Common Stock
Upstream Bio Inc
Adam Houghton Chief Business Officer Sale of securities on an exchange or to another person at price $ 5.49 per share. 16 Sep 2026 700 22,901 - 5.5 3,843 Common Stock
United Therapeutics Corp
Martine A. Rothblatt Director, Chairperson & CEO Sale of securities on an exchange or to another person at price $ 500.20 per share. 16 Sep 2026 492 330,151 (0%) 0% 500.2 246,096 Common Stock
Upstream Bio Inc
Allison Ambrose General Counsel Sale of securities on an exchange or to another person at price $ 5.49 per share. 16 Sep 2026 485 15,563 - 5.5 2,663 Common Stock
Harmony Biosciences Holdings Inc
Kumar Budur CHIEF MEDICAL OFFICER Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 16 Sep 2026 400 62,946 - - Stock Option
Harmony Biosciences Holdings Inc
Kumar Budur CHIEF MEDICAL OFFICER Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 16 Sep 2026 400 29,000 - - Stock Option
Harmony Biosciences Holdings Inc
Kumar Budur CHIEF MEDICAL OFFICER Exercise or conversion of derivative security received from the company (such as an option) at price $ 30.27 per share. 16 Sep 2026 400 13,915 - 30.3 12,108 Common Stock
Harmony Biosciences Holdings Inc
Kumar Budur CHIEF MEDICAL OFFICER Exercise or conversion of derivative security received from the company (such as an option) at price $ 30.69 per share. 16 Sep 2026 400 13,515 - 30.7 12,276 Common Stock
PTC Therapeutics Inc
Michael Schmertzler Director Sale of securities on an exchange or to another person at price $ 68.45 per share. 16 Sep 2026 376 1,296,594 (2%) 0% 68.4 25,737 Common Stock
Revolution Medicines Inc
Alan B. Sandler Chief Development Officer Sale of securities on an exchange or to another person at price $ 199.30 per share. 16 Sep 2026 336 52,868 (0%) 0% 199.3 66,966 Common Stock
Corcept Therapeutics Inc
Roberto Wandenkolk Vieira President, Oncology Sale of securities on an exchange or to another person at price $ 100.82 per share. 16 Sep 2026 296 3,946 (0%) 0% 100.8 29,843 Common Stock
Revolution Medicines Inc
Mark A. Goldsmith Director, See Remarks Sale of securities on an exchange or to another person at price $ 195.01 per share. 16 Sep 2026 213 267,117 (0%) 0% 195.0 41,537 Common Stock
United Therapeutics Corp
Martine A. Rothblatt Director, Chairperson & CEO Sale of securities on an exchange or to another person at price $ 505.20 per share. 16 Sep 2026 120 324,443 (0%) 0% 505.2 60,624 Common Stock
Revolution Medicines Inc
Stephen M. Kelsey See Remarks Sale of securities on an exchange or to another person at price $ 195.01 per share. 16 Sep 2026 85 291,791 (0%) 0% 195.0 16,576 Common Stock
Revolution Medicines Inc
Margaret A. Horn Chief Operating Officer Sale of securities on an exchange or to another person at price $ 195.01 per share. 16 Sep 2026 76 154,571 (0%) 0% 195.0 14,821 Common Stock
Revolution Medicines Inc
Jack Anders Chief Financial Officer Sale of securities on an exchange or to another person at price $ 195.00 per share. 16 Sep 2026 61 123,208 (0%) 0% 195 11,895 Common Stock
Revolution Medicines Inc
Jeffrey Cislini SVP & General Counsel Sale of securities on an exchange or to another person at price $ 195.00 per share. 16 Sep 2026 52 55,855 (0%) 0% 195 10,140 Common Stock
Revolution Medicines Inc
Anthony Mancini See Remarks Sale of securities on an exchange or to another person at price $ 195.04 per share. 16 Sep 2026 27 43,863 (0%) 0% 195.0 5,266 Common Stock
Revolution Medicines Inc
Alan B. Sandler Chief Development Officer Sale of securities on an exchange or to another person at price $ 195.00 per share. 16 Sep 2026 5 53,204 (0%) 0% 195 975 Common Stock
Artiva Biotherapeutics Inc
Fred Aslan Director, Chief Executive Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 15 Sep 2026 315,000 315,000 - - Employee Stock Option (Right to Buy)
FibroBiologics Inc
Hamid Khoja Chief Scientific Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 15 Sep 2026 298,508 298,508 - - Warrant (Right to Buy)
FibroBiologics Inc
Hamid Khoja Chief Scientific Officer Grant, award, or other acquisition of securities at price $ 1.68 per share. 15 Sep 2026 298,508 301,571 - 1.7 500,001 Common Stock
AN2 Therapeutics Inc
Cameron C Trenor Chief Medical Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 15 Sep 2026 233,333 233,333 - - Stock Option (right to by)
Travere Therapeutics Inc
Eric M. Dube Director, CHIEF EXECUTIVE OFFICER Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 15 Sep 2026 195,841 108,493 - - Employee stock option (right to buy)
Travere Therapeutics Inc
Eric M. Dube Director, CHIEF EXECUTIVE OFFICER Exercise or conversion of derivative security received from the company (such as an option) at price $ 23.34 per share. 15 Sep 2026 195,841 628,727 (1%) 0% 23.3 4,570,929 Common Stock
Whitehawk Therapeutics Inc
David James Lennon Director, CHIEF EXECUTIVE OFFICER Grant, award, or other acquisition of securities at price $ 0.00 per share. 15 Sep 2026 193,957 193,957 - - Restricted Stock Units
Whitehawk Therapeutics Inc
David James Lennon Director, CHIEF EXECUTIVE OFFICER Grant, award, or other acquisition of securities at price $ 0.00 per share. 15 Sep 2026 193,957 193,957 - - Stock option (right to buy)
Whitehawk Therapeutics Inc
David James Lennon Director, CHIEF EXECUTIVE OFFICER Grant, award, or other acquisition of securities at price $ 0.00 per share. 15 Sep 2026 193,957 193,957 - - Restricted Stock Units
Whitehawk Therapeutics Inc
David James Lennon Director, CHIEF EXECUTIVE OFFICER Grant, award, or other acquisition of securities at price $ 0.00 per share. 15 Sep 2026 193,957 193,957 - - Stock option (right to buy)
Whitehawk Therapeutics Inc
Scott Giacobello CHIEF FINANCIAL OFFICER Grant, award, or other acquisition of securities at price $ 0.00 per share. 15 Sep 2026 118,476 118,476 - - Restricted Stock Units
Whitehawk Therapeutics Inc
Scott Giacobello CHIEF FINANCIAL OFFICER Grant, award, or other acquisition of securities at price $ 0.00 per share. 15 Sep 2026 118,476 118,476 - - Stock Option (right to buy)
Whitehawk Therapeutics Inc
Scott Giacobello CHIEF FINANCIAL OFFICER Grant, award, or other acquisition of securities at price $ 0.00 per share. 15 Sep 2026 118,476 118,476 - - Stock Option (right to buy)
Whitehawk Therapeutics Inc
Scott Giacobello CHIEF FINANCIAL OFFICER Grant, award, or other acquisition of securities at price $ 0.00 per share. 15 Sep 2026 118,476 118,476 - - Restricted Stock Units
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc  
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges

This section tracks all disclosures required by the U.S. Securities and Exchange Commission (SEC) under the Securities Exchange Act of 1934, particularly those related to Section 16 and Rule 10b-5, which govern insider trading activities in the U.S. market. These disclosures are made by corporate insiders, including executives, officers, directors, significant employees, and large shareholders, who are buying and selling stock in their own companies. You can search and filter within these results. You can also sort the information by clicking on the column headers.